# Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

> **NCT05123755** · PHASE2 · RECRUITING · sponsor: **Vasomune Therapeutics, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Acute Respiratory Distress Syndrome
- Viral or Bacterial Infections
- Pneumonia
- Pneumonia, Viral
- Respiratory Infection
- COVID-19 Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** AV-001 Injection
- **DRUG:** AV-001 Placebo Injection

## Key facts

- **NCT ID:** NCT05123755
- **Lead sponsor:** Vasomune Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-20
- **Primary completion:** 2026-05
- **Final completion:** 2026-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123755, "Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05123755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*